Adaptive Sensory Technology Inc

Adaptive Sensory Technology Inc develops precision vision testing platforms that measure contrast sensitivity function (CSF) using personalized, Bayesian adaptive algorithms. The AST Platform quantifies visual function across multiple spatial frequencies and generates comprehensive 'vision graphs' to establish individualized baselines and detect subtle changes in visual performance. The technology is particularly valuable for detecting functional vision changes in patients with diabetic retinopathy, multiple sclerosis, myopia, keratoconus, and other ocular and neurological conditions. The company's quick-CSF (qCSF) methodology has been extensively validated in peer-reviewed literature for superior precision and repeatability compared to standard contrast sensitivity assessments. Products are positioned for ophthalmology clinics, research institutions, and specialized vision centers requiring sensitive outcome measures for clinical trials and patient monitoring. The platform processes millions of data points in real time to personalize testing protocols, enabling rapid assessment of functionally relevant vision changes with clinically meaningful precision.